Dare Bioscience, Inc.
DARE · XNASCIK 1401914fmd_07P4T13QTC4S707PQJXMB7HQFEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Jun 30, 2026, 55 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | – | – | – | – | 0 | 10 | 3 | 0 | 1 |
| Cost of revenue | – | – | – | – | – | – | – | – | 0 | 0 |
| Gross profit | – | – | – | – | – | – | – | – | 0 | 1 |
| Research and development | 0 | 1 | 6 | 9 | 21 | 31 | 30 | 22 | 14 | 6 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | 9 | 9 |
| Total operating expenses | 1 | 11 | 17 | 14 | 27 | 39 | 41 | 34 | 23 | 14 |
| Operating income | (1) | (11) | (17) | (14) | (27) | (39) | (31) | (31) | (23) | (14) |
| Interest expense | 0 | 0 | – | – | – | – | – | – | – | – |
| Interest and investment income | 0 | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (2) | (0) | 0 | 0 | 0 | 0 | 0 | 1 | 1 | (0) |
| Income before taxes | (1) | (12) | (17) | (14) | (27) | (39) | (31) | (30) | (4) | (14) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (12) | (17) | (14) | (27) | (39) | (31) | (30) | (4) | (14) |
| Net income | (1) | (12) | (17) | (14) | (27) | (39) | (31) | (30) | (4) | (13) |
| Net income to common shareholders | (39) | – | (17) | (15) | (27) | (39) | (31) | (30) | (4) | (13) |